Medicare

Treatment for chronic wounds has become a focal point for massive expenditures and a series of investigations into suspected medical fraud in the US. At the center of the controversy are "skin substitutes," with spending in this sector skyrocketing over the past few years.

The administration of US President Donald Trump announced this evening (Tuesday) that it will end the subsidy program designed to curb the rise in premiums for prescription drug insurance plans under Medicare Part D. The decision is expected to affect about 25 million enrollees, with many potentially paying more for drug coverage starting in 2027.